KEYFINSERVStockbroking & Allied
Keynote Financial Services Limited — Profit & Loss Statement
₹227.55
-6.20%
Keynote Financial Services Limited Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income From Continuing And Discontinued Operation | 14.57 Cr | 26.79 Cr | -1.63 Cr | 16.08 Cr | — |
| Total Expenses | 11.64 Cr | -4.67 Cr | 16.04 Cr | 1.62 Cr | — |
| Diluted NI Availto Com Stockholders | 14.57 Cr | 26.79 Cr | -1.63 Cr | 16.08 Cr | — |
| Net Income Common Stockholders | 14.57 Cr | 26.79 Cr | -1.63 Cr | 16.08 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 14.57 Cr | 26.79 Cr | -1.63 Cr | 16.08 Cr | — |
| Net Income Including Noncontrolling Interests | 14.57 Cr | 26.79 Cr | -1.63 Cr | 16.08 Cr | — |
| Net Income Continuous Operations | 14.57 Cr | 26.79 Cr | -1.63 Cr | 16.08 Cr | — |
| Tax Provision | 0.81 Cr | 7.69 Cr | 1.66 Cr | 2.59 Cr | — |
| Pretax Income | 11.55 Cr | 35.49 Cr | -0.05 Cr | 18.67 Cr | — |
| Other Non Operating Income Expenses | 2.43 Cr | 2.29 Cr | 0.08 Cr | 0.29 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.02 Cr | 0.10 Cr | — |
| Net Non Operating Interest Income Expense | -0.73 Cr | -0.29 Cr | 1.46 Cr | 2.45 Cr | — |
| Interest Expense Non Operating | 0.73 Cr | 0.29 Cr | 0.06 Cr | 1.16 Cr | — |
| Operating Income | 9.85 Cr | 33.48 Cr | -1.42 Cr | 15.83 Cr | — |
| Operating Expense | 2.31 Cr | -11.28 Cr | 10.23 Cr | -3.54 Cr | — |
| Other Operating Expenses | 8.23 Cr | 6.45 Cr | 5.65 Cr | 2.10 Cr | — |
| Depreciation And Amortization In Income Statement | 0.91 Cr | 0.78 Cr | 0.63 Cr | 0.69 Cr | — |
| Depreciation Income Statement | 0.91 Cr | 0.78 Cr | 0.63 Cr | 0.69 Cr | — |
| Gross Profit | 12.16 Cr | 22.20 Cr | 8.81 Cr | 12.29 Cr | — |
| Cost Of Revenue | 9.33 Cr | 6.61 Cr | 5.82 Cr | 5.16 Cr | — |
| Total Revenue | 21.49 Cr | 28.81 Cr | 14.63 Cr | 17.45 Cr | — |
| Operating Revenue | 21.49 Cr | 28.81 Cr | 14.63 Cr | 17.45 Cr | — |
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.05 Cr | 0.01 Cr | — |
| Tax Rate For Calcs | 0.07 | 0.22 | 0.30 | 0.14 | — |
| Normalized EBITDA | 13.19 Cr | 36.56 Cr | 0.81 Cr | 20.42 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -0.18 Cr | 0.10 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -0.18 Cr | 0.10 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 14.57 Cr | 26.79 Cr | -1.63 Cr | 16.08 Cr | — |
| Reconciled Depreciation | 0.91 Cr | 0.78 Cr | 0.63 Cr | 0.69 Cr | — |
| Reconciled Cost Of Revenue | 9.33 Cr | 6.61 Cr | 5.82 Cr | 5.16 Cr | — |
| EBITDA | 13.19 Cr | 36.56 Cr | 0.64 Cr | 20.52 Cr | — |
| EBIT | 12.28 Cr | 35.78 Cr | 69000.00 | 19.83 Cr | — |
| Net Interest Income | -0.73 Cr | -0.29 Cr | 1.46 Cr | 2.45 Cr | — |
| Interest Expense | 0.73 Cr | 0.29 Cr | 0.06 Cr | 1.16 Cr | — |
| Normalized Income | 14.57 Cr | 26.79 Cr | -1.51 Cr | 16.00 Cr | — |
| Rent Expense Supplemental | — | 0.27 Cr | 0.17 Cr | 0.33 Cr | 0.22 Cr |
| Diluted Average Shares | — | 0.70 Cr | 0.56 Cr | 0.56 Cr | 0.56 Cr |
| Basic Average Shares | — | 0.70 Cr | 0.56 Cr | 0.56 Cr | 0.56 Cr |
| Diluted EPS | — | 38.16 | -3.07 | 28.89 | 20.25 |
| Basic EPS | — | 38.16 | -3.07 | 28.89 | 20.25 |
| Minority Interests | — | 0.00 | 0.00 | 0.00 | — |
| Write Off | — | -9000.00 | -0.02 Cr | -0.10 Cr | 0.18 Cr |
| Total Other Finance Cost | — | 0.11 Cr | 0.20 Cr | 0.03 Cr | 33000.00 |
| Interest Income Non Operating | — | 2.38 Cr | 1.72 Cr | 3.63 Cr | 3.22 Cr |
| Selling General And Administration | — | 3.85 Cr | 3.21 Cr | 3.11 Cr | 2.16 Cr |
| Selling And Marketing Expense | — | 0.33 Cr | 0.09 Cr | 0.04 Cr | 0.10 Cr |
| General And Administrative Expense | — | 3.52 Cr | 3.12 Cr | 3.07 Cr | 2.07 Cr |
| Rent And Landing Fees | — | 0.27 Cr | 0.17 Cr | 0.33 Cr | 0.22 Cr |
| Interest Income | — | 2.38 Cr | 1.72 Cr | 3.63 Cr | 3.22 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Keynote Financial Services Limited
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.